Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenström macroglobulinemia

Blood

Volumn 109, Issue 11, 2007, Pages 4964-4972

  Moreau, Anne Sophie ^a,b,c   Jia, Xiaoying ^a   Ngo, Hai T ^a   Leleu, Xavier ^a,b,c   O'Sullivan, Garrett ^a   Alsayed, Yazan ^d   Leontovich, Alexey ^e   Podar, Klaus ^a,b   Kutok, Jeffrey ^a,b   Daley, John ^a   Lazo Kallanian, Suzan ^a   Hatjiharissi, Evdoxia ^a,b   Raab, Marc S ^a,b   Xu, Lian ^a   Treon, Steven P ^a,b   Hideshima, Teru ^a,b   Anderson, Kenneth C ^a,b   Ghobrial, Irene M ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CASPASE 3; CASPASE 8; CASPASE 9; CATHA EDULIS EXTRACT; ENZASTAURIN; FLUDARABINE; MARCKS PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE B; PROTEIN KINASE C BETA; PROTEIN KINASE C INHIBITOR; PROTEIN S6;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; PROTEIN MICROARRAY; PROTEIN PHOSPHORYLATION; STROMA CELL; TUMOR GROWTH; UPREGULATION; WALDENSTROEM MACROGLOBULINEMIA;

EID: 34249746834     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-10-054577     Document Type: Article

References (25)

1. Ghobrial IM, Gertz MA, Fonseca R. Waldenstrom macroglobulinaemia. Lancet Oncol. 2003;4:679-685.
2. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003;30:110-115.
3. Treon SP, Gertz MA, Dimopoulos M, et al. Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia. Blood. 2006;107:3442-3446.
4. Gertz MA, Anagnostopoulos A, Anderson K, et al. Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003;30:121-126.
5. Goekjian PG, Jirousek MR. Protein kinase C inhibitors as novel anticancer drugs. Expert Opin Investig Drugs. 2001;10:2117-2140.
6. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med. 2002;8:68-74.
7. Hans CP, Weisenburger DD, Greiner TC, et al. Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma. Mod Pathol. 2005;18:1377-1384.
8. Abrams ST, Lakum T, Lin K, et al. B-cell receptor signalling in chronic lymphocytic leukemia cells is regulated by overexpressed active protein kinase CβII. Prepublished on September 26, 2006, as DOI 10.1182/blood-2006-03- 012021. (Now available as Blood. 2007;109:1193-1201.)
9. Podar K, Tai YT, Davies FE, et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood. 2001;98:428-435.
10. Graff JR, McNulty AM, Hanna KR, et al. The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res. 2005;65:7462-7469.
11. Podar K, Raab MS, Zhang J, et al. Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl). Prepublished on October 5, 2006, as DOI 10.1182/blood-2006-08-042747. (Now available as Blood. 2007;109:1669-1677.)
12. Keyes KA, Mann L, Sherman M, et al. LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice. Cancer Chemother Pharmacol. 2004;53:133-140.
13. Santos D HA, Tournilhac O, Leleu X, et al. Establishment of a Waldenstrom's macroglobulinemia cell line (BCWM.1) with productive in vivo engraftment in SCID-hu mice. Blood. 2005;106:288a. Abstract 979.
14. Al-Katib AM, Mensah-Osman E, Aboukameel A, Mohammad R. The Wayne State University Waldenstrom's macroglobulinemia preclinical model for Waldenstrom's macroglobulinemia. Semin Oncol. 2003;30:313-317.
15. Ghobrial IM, McCormick DJ, Kaufmann SH, et al. Proteomic analysis of mantle-cell lymphoma by protein microarray. Blood. 2005;105:3722-3730.
16. Tassone P, Neri P, Kutok JL, et al. A SCID-hu in vivo model of human Waldenstrom macroglobulinemia. Blood. 2005;106:1341-1345.
17. Hideshima T, Catley L, Yasui H, et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Prepublished on January 17, 2006, as DOI 10.1182/blood-2005-08-3434. (Now available as Blood. 2006;107:4053-4062.)
18. Dillon CP, Sandy P, Nencioni A, Kissler S, Rubinson DA, Van Parijs L. Rnai as an experimental and therapeutic tool to study and regulate physiological and disease processes. Annu Rev Physiol. 2005;67:147-173.
19. Rubinson DA, Dillon CP, Kwiatkowski AV, et al. A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet. 2003;33:401-406.
20. Tai YT, Li X, Tong X, et al. Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. Cancer Res. 2005;65:5898-5906.
21. Hatzimichael EC, Christou L, Bai M, Kolios G, Kefala L, Bourantas KL. Serum levels of IL-6 and its soluble receptor (sIL-6R) in Waldenstrom's macroglobulinemia. Eur J Haematol. 2001;66:1-6.
22. Mitsiades CS, Mitsiades NS, Munshi NC, Richardson PG, Anderson KC. The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. Eur J Cancer. 2006;42:1564-1573.
23. Tassone P, Neri P, Carrasco DR, et al. A clinically relevant SCID-hu in vivo model of human multiple myeloma. Blood. 2005;106:713-716.
24. Querfeld C, Rizvi MA, Kuzel TM, et al. The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway. J Invest Dermatol. 2006;126:1641-1647.
25. Dimopoulos MA, Anagnostopoulos A. Waldenstrom's macroglobulinemia. Best Pract Res Clin Haematol. 2005;18:747-765.